Haas Jason
SEC Form 4 insider trading activity
Haas Jason has filed 4 SEC Form 4 filings (8 transaction rows) across 2 companies, including LGND, ODTX, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Aug 14, 2026.
On the most recent filing, Haas Jason is listed as Director at LIGAND PHARMACEUTICALS INC. Inside the rolling window, Haas Jason reported 1 open-market purchase totaling $20K in ODTX and 2 open-market sales totaling $3.7M in LGND. The largest disclosed transaction in the window is a sale of 7,138 LGND shares on Aug 12, 2026, worth $2.1M.
Companies traded
Other insiders at LGND
Insider Buying
$20K
reported purchases (SEC code P)
Insider Selling
$3.7M
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Haas Jason made?
Haas Jason has filed 4 SEC Form 4 filings (8 transaction rows) across 2 companies, including LGND, ODTX since 2026.
Which companies does Haas Jason trade?
Haas Jason has filed SEC Form 4 disclosures for 2 companies, including LGND, ODTX.
When was Haas Jason's most recent SEC Form 4 filing?
Haas Jason's most recent SEC Form 4 filing on Tracefour is dated Aug 14, 2026.
What is Haas Jason's total buy and sell value in the current window?
Inside the rolling retention window, Haas Jason bought $20K and sold $3.7M based on SEC Form 4 filings.
What was Haas Jason's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 7,138 LGND shares on 2026-08-12, worth $2.1M, per SEC Form 4 filings.